+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Ocrevus"

From
Multiple Sclerosis Treatment Global Market Report 2025 - Product Thumbnail Image

Multiple Sclerosis Treatment Global Market Report 2025

  • Report
  • July 2025
  • 175 Pages
  • Global
From
Multiple Sclerosis Drugs Market Report 2025 - Product Thumbnail Image

Multiple Sclerosis Drugs Market Report 2025

  • Report
  • April 2025
  • 250 Pages
  • Global
From
Neurological Disorder Drugs Market Report 2025 - Product Thumbnail Image

Neurological Disorder Drugs Market Report 2025

  • Report
  • April 2025
  • 200 Pages
  • Global
From
CNS Therapeutics - Global Strategic Business Report - Product Thumbnail Image

CNS Therapeutics - Global Strategic Business Report

  • Report
  • July 2025
  • 898 Pages
  • Global
From
From
Relapsing Multiple Sclerosis Pipeline Analysis Report 2025 - Product Thumbnail Image

Relapsing Multiple Sclerosis Pipeline Analysis Report 2025

  • Report
  • June 2025
  • 200 Pages
  • Global
From
Multiple Sclerosis Drugs Market Analysis & Forecast to 2024-2034 - Product Thumbnail Image

Multiple Sclerosis Drugs Market Analysis & Forecast to 2024-2034

  • Report
  • January 2024
  • 200 Pages
  • Global
From
From
From
Multiple Sclerosis: Dynamic Market Forecast to 2026 - Product Thumbnail Image

Multiple Sclerosis: Dynamic Market Forecast to 2026

  • Report
  • November 2018
  • 53 Pages
  • Global
From
Multiple Sclerosis Forecast and Market Analysis to 2025 - Product Thumbnail Image

Multiple Sclerosis Forecast and Market Analysis to 2025

  • Report
  • July 2018
  • 765 Pages
  • Global
From
  • 13 Results (Page 1 of 1)
Loading Indicator

Ocrevus is a Central Nervous System (CNS) drug developed by Genentech, a member of the Roche Group, for the treatment of multiple sclerosis (MS). It is the first and only approved therapy for both relapsing and primary progressive forms of MS. Ocrevus is a monoclonal antibody that works by targeting a protein called CD20, which is found on the surface of certain immune cells. This helps to reduce the number of these cells, which can cause inflammation and damage to the nerves in MS patients. The CNS drug market is a rapidly growing sector, with a range of treatments available for various neurological conditions. Ocrevus is one of the most widely used drugs in this market, and is used to treat MS, a condition that affects millions of people worldwide. Other drugs in this market include Tecfidera, Gilenya, and Aubagio, which are used to treat MS, as well as drugs for Parkinson's disease, Alzheimer's disease, and epilepsy. Companies in the Ocrevus market include Genentech, Novartis, Biogen, Merck, and Sanofi. Show Less Read more